Weight-Loss drug may slow uterine tumors before surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * The subject is willing and able to comply with study procedures based on the judgement of the investigator. * Age \> 18 years at the time of consent. * ECOG ≤ 2 or Karnofsky Performance Status of \>50 * Histological or cytological evidence/confirmation of endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid histology endometrial cancer (EC) and scheduled to undergo standard of care hysterectomy and staging. * Subject must have archival EC tissue available. * Body mass index of \>30kg/m2 * Demonstrate adequate organ function as defined in the protocol, all screening labs to be obtained within 28 days prior to initiating study treatment Exclusion Criteria: * Active infection requires systemic therapy. * Subject is pregnant or breast breastfeeding, or planning to become pregnant at any time during the study * Taking any prescription medications or other drugs that influence weight change in the past 3 months. * Known sensitivities (i.e., urticaria and eczema) to GIP and GLP-1 receptor agonists. * Have type 1 diabetes mellitus or latent autoimmune diabetes in adults, or are receiving treatment with insulin. * Have a history of severe hypoglycemia or not be able to communicate an understanding of hypoglycemic symptoms. * Have a history of acute or chronic pancreatitis or serum lipase/amylase \>2X ULN or fasting triglyceride \>500 mg/dL at screening. * Have a diagnosis of gastroparesis, history of bariatric surgery, or a clinically significant gastric emptying abnormality. * Have a history or family history of multiple endocrine neoplasia, thyroid C-cell hyperplasia, or medullary thyroid carcinoma. * Currently receiving another treatment for EIN or EC. * Any condition, in the opinion of the investigator, which would prohibit safe participation.